AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of the Claims:

1. – 26. Canceled.

27. (Currently Amended) A method of treating, ~~preventing,~~ modifying or managing radiculopathy ~~pain~~, which comprises administering to a patient having radiculopathy a therapeutically ~~or prophylactically~~ effective amount of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline~~a compound~~ of the formula,



~~in which~~

~~Y is oxygen or H_2;~~

~~a first of R^1 and R^2 is halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, the second of R^1 and R^2, independently of the first, is hydrogen, halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, and~~

~~R^3 is hydrogen, alkyl, or benzyl;~~

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

28. Canceled.

29. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline ~~1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline~~.

30. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is a pharmaceutically acceptable salt.

31. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is a pharmaceutically acceptable solvate.

32. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is a pharmaceutically acceptable stereoisomer.

33. (Previously Presented) The method of claim 32, wherein the stereoisomer is an enantiomerically pure R isomer.

34. (Previously Presented) The method of claim 32, wherein the stereoisomer is an enantiomerically pure S isomer.

35. (Currently Amended) The method of claim 27 ~~or 28~~, which further comprises administering a therapeutically ~~or prophylactically~~ effective amount of a second active agent.

36. (Previously Presented) The method of claim 35, wherein the second active agent is an antidepressant, antihypertensive, anxiolytic, calcium channel blocker, alpha-adrenergic receptor agonist, alpha-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, anti-inflammatory agent, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, cox-2 inhibitor, hyperbaric oxygen, or a combination thereof.

37. (Previously Presented) The method of claim 35, wherein the second active agent is salicylic acid acetate, celecoxib, ketamine, gabapentin, carbamazepine, oxcarbazepine, phenyloin, sodium valproate, prednisone, nifedipine, clonidine, oxycodone, meperidine, morphine sulfate, hydromorphone, fentanyl, acetaminophen, ibuprofen, naproxen sodium, griseofulvin, amitriptyline, imipramine or doxepin.

38. – 43. Canceled.

44. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is administered orally.

45. (Previously Presented) The method of claim 44, wherein the compound is administered in the form of a capsule or tablet.

46. (Currently Amended) The method of claim 27 ~~or 28~~, wherein the compound is administered in an amount of from about 0.1 to about 150 mg per day.

47. (Currently Amended) The method of claim 27 [[28]], wherein the compound is administered in an amount of from about 5 [[0.1]] to about 50 mg per day.

48. (Currently Amended) The method of claim 47, wherein the compound is administered in an amount of from about 5 [[0.5]] to about 25 mg per day.

49. (Currently Amended) The method of claim 47, wherein the compound is administered in an amount of ~~from~~ about 25 ~~2 to about 10~~ mg per day.

50. (Currently Amended) The method of claim 47, wherein the compound is administered in an amount of about 10 [[5]] mg per day.